Pembrolizumab (Keytruda) has been registered for use in combination with tyrosine kinase inhibitor axitinib (Inlyta) for the first-line treatment of patients with advanced renal cell carcinoma. It represents the fifteenth indication for MSD’s checkpoint inhibitor in Australia. The TGA registration is based on the results of the KEYNOTE-426 trial, published in the NEJM last year, ...
New indication for pembrolizumab in advanced RCC
30 Jun 2020